Key statistics dashboard for Context Therapeutics Inc. (CNTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Stock Data
| Price | $0.38 |
| Market Cap | $35M |
| Beta | 1.83 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.76 |
| Price / Book | 0.91 |
| P/S | 0.00 |
| P/FCF | -0.98 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 5.81 |
| Quick Ratio | 5.81 |
| Cash Ratio | 5.45 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.53% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 6.94 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.40 |
| Cash per share | 0.45 |
| FCF per share | -0.36 |
| Tangible Book Value per share | 0.40 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 1.00 |
Related companies: CLNN · CNTB · IFRX · IMA · KLRS · MGNX · ORMP
Explore sector: Healthcare · Biotechnology
More sections of CNTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks